Legal & regulatory framework
Legal & regulatory.
Per-region frameworks. WADA-banned reference.
How research-use-only labelling intersects with each region's regulator. Plus the WADA-banned compound reference for tested athletes.
Research-use only — site-wide stance
Every product mentioned on this site is research-use only. We do not make therapeutic claims, do not recommend self-administration, and do not have a doctor-patient relationship with visitors. Visitors who order from any vendor do so under their own responsibility and the vendor's terms of sale.
Per-region regulatory frameworks
| Region | Framework |
|---|---|
| EU | EMA + EU DSA + GDPR. Research-use-only labelled. No therapeutic claims. |
| DE | Heilmittelwerbegesetz (HWG, 1965) + BfArM. Strictly research-use-only labelled. Therapeutic claims trigger HWG penalties up to €50,000 or 1 year imprisonment. NADA Deutschland is WADA-compliant for tested athletes. |
| US | FDA + FTC research-use-only framework. No therapeutic claims. SARMs are state-scheduled in California and other states; we do not cover SARMs as research peptides. WADA S0 / S2 banned compounds (BPC-157, IGF-1 LR3, CJC-1295, Ipamorelin) — tested athletes verify with USADA. |
| CA | Health Canada + CBSA + provincial frameworks. Research-use-only labelled. Quebec residents: Bill 96 (Loi sur la langue officielle et commune du Québec) compliance via bilingual EN/FR vendor selection. |
| AU/NZ | TGA Schedule 4 (most research peptides classified prescription-only). Personal importation requires TGA permit or prescription. ABF customs discretion applies. Medsafe (NZ) parallels TGA framework. |
| JP | PMD Act: a medicine needs MHLW product approval (Article 14), and unapproved medicines may not be sold or advertised. Personal imports above set limits (one month's supply of prescription drugs, two months' of most other medicines) need an import confirmation certificate (輸入確認証), which replaced Yakkan Shoumei in September 2020. |
| SEA | Per-country: Thailand FDA (more permissive), Singapore HSA (BPC-157 banned 2019, do not order), Malaysia / Vietnam / Philippines / Indonesia (intermediate frameworks). We do not ship to Singapore. |
| GCC | UAE Ministry of Health + Dubai Health Authority (most permissive). SFDA Saudi Arabia (more restrictive). Qatar (MoPH), Kuwait (MoH), Bahrain (NHRA), Oman (MoH) — intermediate. |
| AFRICA | SAHPRA (South Africa) — no research-use-only category: SAHPRA's May 2026 public notice lists BPC-157 and other research peptides as illegally marketed, and personal orders from abroad need a Section 21 authorisation. NAFDAC (Nigeria), MoH (Kenya, Egypt, Morocco) — varies. |
| LATAM | Cofepris (Mexico), ANMAT (Argentina), ISP (Chile), INVIMA (Colombia), DIGEMID (Peru). Heterogeneous frameworks — research-use-only declarations help, customs discretion applies. |
| BR | ANVISA (Agência Nacional de Vigilância Sanitária). Operates under Lei nº 9.782/1999; personal imports of medicines by individuals are governed by Chapter XII of RDC nº 81/2008 (as amended by RDC nº 28/2011). Research-use-only labelled ("uso exclusivamente para fins de pesquisa científica"). Personal importation of research compounds permitted with declaration; therapeutic claims or sale as medicine trigger ANVISA enforcement. Receita Federal may inspect international shipments — declarations must be consistent with package contents. Research peptides are not ANVISA-registered medicines and have no human therapeutic-use approval. |
| RU | FZ-152 (Personal Data Protection, 2006) — operator handles data localization. Roskomnadzor compliance for the Russian-language deploy. Ministry of Health + Roszdravnadzor framework. Liberal stance on research-use-only peptides for personal research. |
WADA-banned compound reference
WADA (World Anti-Doping Agency) maintains a Prohibited List updated annually. Compounds below are on the 2026 List. Tested athletes must verify with their National Anti-Doping Organization (NADO — NADA Deutschland, USADA, ASADA, RUSADA, etc.) before any use. Sanctions include 2-year suspensions for first violation under the WADA Code.
| Compound | WADA class | Notes |
|---|---|---|
| BPC-157 | S0 (named since 2022) | Body Protection Compound |
| TB-500 | S2 (growth factors) | Thymosin Beta-4 fragment |
| IGF-1 LR3 | S2.4 (growth factors) | Long Arg3 IGF-1 |
| CJC-1295 | S2.5 (GH-releasing factors) | with or without DAC |
| Ipamorelin | S2.5 (GH-releasing factors) | selective GHS-R1a agonist |
| GHK-Cu (injectable) | S0 (non-approved substances) | topical/cosmetic forms not on the List |
| MGF / Mecano-Growth Factor | S2.4 (growth factors) |
This page is operations / regulatory reference. It is not legal advice. Consult qualified counsel licensed in your jurisdiction.